Massimo Group (NASDAQ:MAMO), Inc. engages in the design, development, manufacture and sale of a broad spectrum of consumer and medical products. The company operates through two primary business segments: Nutritional and OTC Consumer Products, which includes dietary supplements, nutraceuticals and personal care items; and Medical Products and Drug Delivery Devices, encompassing nasal sprays, inhalation devices, medical adhesives and related equipment. Massimo Group also offers contract manufacturing services and private-label capabilities, serving customers ranging from established consumer brands to emerging healthcare companies.
With manufacturing facilities in Asia and a growing distribution network across North America, Europe, Latin America and Asia-Pacific, Massimo Group combines scale in production with a flexible, customer-focused approach. Its plants in China and Malaysia are certified for Good Manufacturing Practices (GMP) and routinely inspected by regulatory bodies to ensure compliance with international quality standards. The company’s supply chain management and logistics infrastructure support both bulk ingredient sourcing and finished-package distribution, allowing for rapid response to shifting market demands.
Founded on a heritage of medical product innovation in China, Massimo Group has expanded its footprint by acquiring complementary businesses and investing in research and development. This strategic growth has enabled the company to introduce proprietary formulations, advanced device platforms and enhanced packaging solutions. Massimo’s executive team combines industry veterans from pharmaceutical, consumer goods and medical-device sectors, with CEO Dong Ma leading initiatives in product development, strategic partnerships and global expansion.
As Massimo Group continues to build its portfolio of branded and private-label offerings, it remains focused on leveraging technology, regulatory expertise and supply-chain efficiencies. By blending its roots in healthcare manufacturing with its growing consumer brands, the company aims to capture new opportunities in the wellness market, strengthen its position in specialty drug delivery and deliver comprehensive solutions to an evolving base of global customers.
